Adalimumab Biosimilar Antibody

Adalimumab, sold under the brand name Humira, is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis.

TNF is a naturally occurring cytokine that plays a role in normal inflammatory and immune responses. Increased levels of TNF are found in the joint synovial fluid of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients, and play an imperative role in pathologic inflammation and joint destruction that are major complications of these diseases. Adalimumab binds with specificity to tumor necrosis factor-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors.